Weed Got Four Times Stronger and Nobody Sent a Memo. The FDA Just Noticed.

R5 didn’t quit cannabis because a doctor warned her about potency data. She quit because, in her own words to researchers afterward, “I don’t want to live like this anymore. So, I was really desperate.” She’d been using daily for over a year after a diagnosis of severe mental illness, one of twelve participants in a 2024 study in BJPsych Bulletin who’d stayed abstinent at least six months. Her advice to the next person in her position wasn’t gentle: “Don’t try to fix it alone purely on willpower. You cannot do this alone.”

The cannabis most people picture when they hear the word hasn’t existed in a dispensary for years — what’s actually sold now is strong enough that the FDA just decided the public needs to be told.

The FDA announced this week it’s building public health messaging specifically about cannabis potency, product formulations, and manufacturing — the first time the agency has treated “how strong is this, really” as something the public doesn’t already know. That’s worth sitting with, because the number most people carry in their heads about weed is decades out of date.

The plant didn’t get stronger. The industry made a different product and kept the old name.

In 1995, cannabis seized and tested through NIDA’s potency monitoring program averaged 3.96% THC. By 2022, that average had climbed to 16.14% — roughly four times stronger, under the same word, sold in the same kind of bag. That number describes flower. It doesn’t describe what’s actually driving today’s dispensary sales: concentrates. Dabs, wax, shatter, and distillate cartridges now commonly test at 60% to 90% THC, a category of product that functionally didn’t exist for the average consumer a generation ago.

Here’s the biology in plain terms: THC works by binding to receptors in your brain that are normally activated by the body’s own cannabinoid chemicals, the ones that help regulate mood, appetite, memory, and stress response. Use a low-potency product occasionally and that system mostly bounces back on its own. Flood it daily with something four to twenty times stronger than what your brain evolved managing, and the system adapts by downregulating — turning down its own natural signaling to compensate for the constant flood. That adaptation is what makes stopping feel like withdrawal instead of just “going back to normal”: the brain has to relearn how to run its own reward and mood chemistry without the assist.

That process has a name and a diagnosis code most people have never heard, because for most of cannabis’s cultural life in America, “you can’t get addicted to weed” was closer to received wisdom than medical fact. It wasn’t until the DSM-5, in 2013, that Cannabis Withdrawal Syndrome became an official diagnosis at all — decades after alcohol and opioid withdrawal were already textbook material, and roughly the same era legalization started sweeping state ballots. The clinical recognition and the commercial potency boom happened on the same timeline, not by coincidence: more people using stronger products for longer is exactly the condition that makes a withdrawal syndrome visible enough to finally name.

What withdrawal actually looks like, and how common it really is

A 2026 clinical review in the Journal of Military, Veteran and Family Health puts real numbers on how common this now is: roughly 47% of regular or dependent users experience Cannabis Withdrawal Syndrome, a rate that climbs to as high as 87% in inpatient clinical settings. In a large U.S. population study cited in the review, 12.1% of frequent cannabis users overall met full CWS criteria — and that group showed meaningfully higher rates of mood, anxiety, and personality disorders, plus greater day-to-day disability, than frequent users who didn’t develop the syndrome.

Symptoms aren’t subtle once they start: irritability and anger, anxiety, insomnia paired with unusually vivid dreams, appetite and weight loss, restlessness, depressed mood, headaches, nausea, sweating. They typically begin 24 to 48 hours after the last use, peak between days two and six, and resolve within one to two weeks — longer, and often worse, for people with a co-occurring psychiatric condition. Risk climbs with younger age at first use, longer duration of use, higher daily doses, smoking or dabbing rather than ingesting, and any existing mental health condition. No medication is currently approved specifically to treat CWS. Cognitive behavioral therapy remains the primary evidence-based option, and the review notes that dronabinol and gabapentin, sometimes tried off-label, don’t have clear evidence behind them either.

Risk climbs with younger age at first use, longer duration of use, higher daily doses, smoking or dabbing rather than ingesting, and any existing mental health condition.

What the Bruins study captured that a symptom list can’t is what actually got people through those two weeks. R2 described the worst of it bluntly: “The sleeping, having to feel things again, makes it hard. Lots of nightmares, sweating.” What worked wasn’t willpower alone — it was concrete, almost stubbornly ordinary supports. R7 adopted a dog: “I adopted a dog, had to go outside daily. Without it I’d have withered.” R2 credited someone checking in constantly: “He came by often, called me, sent messages. He got me through.” None of the twelve participants who’d stayed abstinent for six months described doing it through sheer resolve. They described doing it with a person, a routine, or both.

The social-cultural piece nobody priced in

Legalization made cannabis a normal Tuesday errand in most of the country, and normal is doing a lot of quiet work in that sentence. A dispensary counter doesn’t come with the cultural friction a liquor store used to have around hard liquor, and “it’s just weed” is still the default framing even as the actual product strength has left that framing behind. That gap — old reputation, new pharmacology — is precisely what the FDA’s new messaging effort is aimed at closing, and precisely why cannabis use disorder keeps getting waved off as a smaller problem than the numbers above support.

If you’re the one white-knuckling week two right now: what R2 and R7 describe isn’t a personal failure showing up as insomnia and dread — it’s your brain doing exactly what the biology predicts, on a predictable timeline, and it does end. The thing that got the people in that study through it wasn’t discipline. It was not doing it alone.